Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan;34(1):e14674.
doi: 10.1111/dth.14674. Epub 2020 Dec 25.

Pregnancy and breastfeeding in hidradenitis suppurativa: A review of medication safety

Erin K Collier  1 , Justine R Seivright  1 , Vivian Y Shi  2 , Jennifer L Hsiao  3
Affiliations
Review

Pregnancy and breastfeeding in hidradenitis suppurativa: A review of medication safety

Erin K Collier et al. Dermatol Ther. 2021 Jan.

Abstract

Hidradenitis suppurativa (HS) is a chronic inflammatory disease that disproportionately affects women of childbearing age. Pregnancy influences HS severity for many women, thus diligent continued management throughout pregnancy and postpartum may be required. Herein, we provide an updated review of pregnancy and lactation safety data for HS medications, including topical antiseptic washes, topical and systemic antibiotics, biologic and nonbiologic immunomodulators, immunosuppressants, adjunct medical therapies, and pain medications, to help guide risk-benefit discussions between providers and HS patients.

Keywords: inflammatory disorders; therapy-systemic; therapy-topical.

PubMed Disclaimer

References

REFERENCES

    1. Collier E, Shi VY, Parvataneni RK, Lowes MA, Hsiao JL. Special considerations for women with hidradenitis suppurativa. Int J Women's Dermatol. 2020;6(2):85-88. https://doi.org/10.1016/j.ijwd.2020.02.005.
    1. Garg A, Lavian J, Lin G, Strunk A, Alloo A. Incidence of hidradenitis suppurativa in the United States: a sex- and age-adjusted population analysis. J Am Acad Dermatol. 2017;77(1):118-122. https://doi.org/10.1016/j.jaad.2017.02.005.
    1. Lyons AB, Peacock A, McKenzie SA, et al. Evaluation of hidradenitis suppurativa disease course during pregnancy and postpartum. JAMA Dermatol. 2020;156(6):681-685. https://doi.org/10.1001/jamadermatol.2020.0777.
    1. Food and Drug Administration. Content and format labeling for human prescription drug and biological products: requirements for pregnancy and lactation labeling. Fed Regist. 2014;79(233):72064-72103.
    1. Pernia S, DeMaagd G. The new pregnancy and lactation labeling rule. P T. 2016;41(11):713-715.

Substances

LinkOut - more resources